KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBT (2018 - 2026)

Castle Biosciences' EBT history spans 8 years, with the latest figure at -$2.7 million for Q4 2025.

  • On a quarterly basis, EBT fell 134.42% to -$2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$29.5 million, a 236.87% decrease, with the full-year FY2025 number at -$29.5 million, down 236.87% from a year prior.
  • EBT hit -$2.7 million in Q4 2025 for Castle Biosciences, down from -$386000.0 in the prior quarter.
  • Over the last five years, EBT for CSTL hit a ceiling of $8.3 million in Q3 2024 and a floor of -$29.2 million in Q1 2023.
  • Historically, EBT has averaged -$8.7 million across 5 years, with a median of -$5.6 million in 2021.
  • Biggest five-year swings in EBT: surged 410.31% in 2024 and later plummeted 955.48% in 2025.
  • Tracing CSTL's EBT over 5 years: stood at -$15.2 million in 2021, then plummeted by 35.67% to -$20.6 million in 2022, then soared by 87.64% to -$2.5 million in 2023, then surged by 410.31% to $7.9 million in 2024, then plummeted by 134.42% to -$2.7 million in 2025.
  • Business Quant data shows EBT for CSTL at -$2.7 million in Q4 2025, -$386000.0 in Q3 2025, and -$143000.0 in Q2 2025.